Searched for
POTASSIUM CLAVULANATE
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Centre draws a price line to curb cheap pharma importsIndia has set a minimum import price for essential drug ingredients. The aim is to protect domestic manufacturers from aggressive pricing b...
- Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicinesThe Central Drugs Standard Control Organisation (CDSCO) has flagged over 50 drugs, including Paracetamol, as 'not of standard quality'. The...
- Linking spurious drugs with legitimate manufacturers has severe reputational, financial impact: IPAThe Indian Pharmaceutical Alliance (IPA) has called for a clear distinction between spurious and sub-standard drugs following a CDSCO repor...
- Alkem Labs denies claims of Pan-D, Clavam 625 batches being not-of-standard qualityAlkem Laboratories has denied claims that its products Pan-D and Clavam 625 are of substandard quality. The company stated that an investig...
- CDSCO finds 50 common medicines substandard, including those for fever, blood pressure, diabetes, and acid refluxMore than 50 drugs for common conditions like high blood pressure, acid reflux, and erectile dysfunction have been found to be not-of-stand...
- 'Stop use immediately': Telangana warns of three fake medicines being sold in the marketThe Drugs Control Administration in Telangana has issued a Spurious Drug Alert and Stop Use Notice for drugs claiming to be from 'Meg Lifes...
- Costs of 127 medicines set to go down post NPPA's 5th price capAmong the 127 medications on the NPPA's list are paracetamol, amoxycillin, rabeprazole, and metformin. Patients frequently make use of many...
- Indian companies are paying up to 25 per cent more for China APIsKey APIs have become 12-25% costlier in the past few days amid possible supply disruptions that may squeeze margins and raise drug prices, ...
- Medicines for diabetes, infections to cost 40 per cent lessMedicines widely used to treat diabetes, infections, pain and digestive disorders will cost 5-40 per cent less with immediate effect
- Medicines for diabetes, infections to cost 40% lessMedicines widely used to treat diabetes, infections, pain and digestive disorders will cost 5-40 per cent less with immediate effect.
- Stocks to watch: Ranbaxy Laboratories, Moser Baer, Strides Arcolab, Rolta, Essar OilRanbaxy Laboratories is voluntarily recalling two consignments of one of its antibiotics from the US market, a move that may not impact its...
- Ranbaxy recalls 2 batches of antibiotics from USRanbaxy Laboratories is voluntarily recalling two consignments of one of its antibiotics from the US market.
- Wockhardt opens lower after drug launchWockhardt stock opened the day lower at Rs 94.50 on news that it has launched its new insulin (Glaritus)that has a global market of $2 bill...
- Wockhardt climbs 5% on USFDA nodShares of drugmaker Wockhardt rose more than 5 per cent after its subsidiary in the US had won approval from FDA to market augmentin suspen...
- Ranbaxy gets US nod to mkt its drugGurgaon-based pharmaceutical major Ranbaxy Labs today announced that RLL has received approval from the US Food and Drug Administration to ...
Load More
